article thumbnail

Skinny Label and Induced Infringement: The Saga Continues

FDA Law Blog: Biosimilars

GSK skinny label case , the U.S. Specifically, the Government explained, “[t]he section viii pathway cannot function properly if FDA and generic manufacturers cannot rely on an NDA holder’s representations to the agency regarding which portions of the brand-name drug’s labeling teach patented methods of use.”

article thumbnail

FDA Releases Draft Labeling Guidance for Biosimilar Products

Big Molecule Watch

Last week, FDA released a draft guidance, “ Labeling for Biosimilar and Interchangeable Biosimilar Products ” (“2023 Draft Guidance”) that—when finalized—will revise and replace its July 2018 final guidance, “ Labeling for Biosimilar Products.” The fictitious example provided in the 2023 Draft Guidance is “replicamab-cznm.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EU gives narrower label to Apellis, Sobi’s PNH drug

pharmaphorum

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The post EU gives narrower label to Apellis, Sobi’s PNH drug appeared first on.

article thumbnail

Episode 852: Does Europe Do Apixaban Renal Dosing Better (Safer) Than the US?

Pharmacy Joe

The US labeling states: Anti-FXa activity adjusted for exposure to apixaban was similar across renal function categories. Using inverse probability of treatment weighting analysis, the US labeling recommendation of apixaban 5 mg was associated with a higher risk of bleeding at an incidence rate 4.9 or greater. mg twice daily.

article thumbnail

Episode 852: Does Europe Do Apixaban Renal Dosing Better (Safer) Than the US?

Pharmacy Joe

The US labeling states: Anti-FXa activity adjusted for exposure to apixaban was similar across renal function categories. Using inverse probability of treatment weighting analysis, the US labeling recommendation of apixaban 5 mg was associated with a higher risk of bleeding at an incidence rate 4.9 or greater. mg twice daily.

article thumbnail

6 Digital Tools at the Center of Healthcare Digitalization [INFOGRAPHIC]

Pharma Marketing Network

Download this infographic and learn which 6 digital tools are at the center of digitalization and how the will influence the future of Pharma marketing in 2021 and beyond. Company Email *. The post 6 Digital Tools at the Center of Healthcare Digitalization [INFOGRAPHIC] appeared first on Pharma Marketing Network.

article thumbnail

Digital Tools at the Center of Healthcare Digitalization

Pharma Marketing Network

Get your complimentary copy of "The Publishing Industry: The Soar of Innovation During COVID-19 Fact Sheet". Company Email *. The post Digital Tools at the Center of Healthcare Digitalization appeared first on Pharma Marketing Network.